早期卵巣がん患者に対するカルボプラチンとパクリタキセルの併用療法（低用量パクリタキセルの継続投与の有無を問わず）

基本情報

NCT ID

NCT00003644

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

571

治験依頼者名

GOG Foundation

概要

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether receiving combined carboplatin and paclitaxel plus continued low-dose paclitaxel is more effective than carboplatin and paclitaxel alone for early-stage ovarian cancer. PURPOSE: This randomized phase III trial is studying carboplatin and paclitaxel alone too see how well they work compared to carboplatin and paclitaxel together with continued low-dose paclitaxel in treating patients with early-stage ovarian cancer.

対象疾患

介入

依頼者（Sponsor）

実施施設 (7)